FDA Accepts Supplement for Abreva (Docosanol) by Haleon
The FDA has accepted a supplemental application for Abreva (docosanol) submitted by Haleon.
Published: July 26, 2026
Updated: July 26, 2026
Author: Humanexa Intelligence
Therapeutic area: Dermatology / Cold Sores
Asset: Haleon
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Haleon
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for Abreva signifies a potential shift in the competitive landscape for cold sore treatments. Haleon's enhanced position could lead to increased market share, prompting competitors to reassess their strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for updates on the review process and any subsequent approval outcomes.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.